Ainos, Inc. is a dual platform company that advances artificial intelligence based smelltech technologies and immune therapeutics. The company focuses on commercializing its proprietary scent digitization platform called AI Nose while continuing to develop therapeutic assets from its low dose oral interferon program VELDONA. AI Nose is an AI based electronic olfaction system that combines gas sensor arrays with proprietary artificial intelligence models referred to as a smell language model to digitize scent and volatile organic compound signals into a machine readable format called Smell ID. The technology was initially developed for healthcare settings such as point of care testing and is now being expanded into industrial environments including semiconductor manufacturing robotics and smart manufacturing. VELDONA is a low dose oral interferon alpha formulation designed to modulate immune responses through the oral mucosa targeting rare autoimmune and infectious disease indications.

Ainos generates revenue primarily from the sale of AI Nose hardware systems and from recurring service based offerings tied to its SmellTech platform including data analysis and model updates. The company also derives income from the commercialization of VELDONA pet supplements sold in Taiwan and from potential licensing or partnership arrangements for its VELDONA drug candidates. In addition Ainos may earn revenue through collaborative development agreements and pilot deployments with industrial partners that involve subscription or fee based arrangements for the AI Nose platform.

The company operates through the following segments:.

• AI Nose segment focuses on the development production and commercialization of an AI based electronic olfaction system that digitizes scent into Smell ID for use in healthcare and industrial applications including point of care testing semiconductor manufacturing robotics and smart monitoring.

• VELDONA segment concentrates on the research development and commercialization of a low dose oral interferon alpha formulation aimed at treating rare autoimmune and infectious diseases such as oral warts in HIV positive patients Sjögren syndrome and feline chronic gingivostomatitis while also marketing VELDONA pet supplements in Taiwan.

Ainos occupies a niche position at the intersection of artificial intelligence driven scent sensing and immunomodulatory therapeutics. In the AI based scent detection space the company competes with firms that produce traditional gas sensors and electronic noses while its advantage lies in the trainable smell language model and the ability to deliver Smell ID as a versatile data format. In the low dose interferon arena VELDONA faces competition from established interferon therapies but differentiates itself through oral delivery and reduced side effect profile.

The company serves industrial manufacturers such as a leading semiconductor packaging and testing company and works with commercial partners including Inabata & Co. Ltd. Taiwan Inabata Sangyo Co. Topco Scientific Co. Ltd. Trusval Technology Co. Ltd. Solomon Technology Corporation Kenmec Mechanical Engineering Co. Ltd. Topmed International Biotech Co. Ltd. It also supplies VELDONA pet supplements to pet owners in Taiwan and collaborates with manufacturers such as Taiwan Carbon Nano Technology Corp. and Swiss Pharmaceutical Co. Ltd. for production of its devices and formulations.